BANGALORE -(Dow Jones)- Lupin Ltd. (500257.BY) Friday said its U.S unit has received final approval from the U.S. Food and Drug Administration to sell its generic version of nabumetone tablets--in 500 milligram and 750 mg strengths--used for the treatment of osteoarthritis and rheumatoid arthritis.

Lupin's nabumetone is the generic equivalent of GlaxoSmithKline PLC's (GSK) Relafen tablets.

U.S. sales of nabumetone were $66.8 million for the 12 months ended September 2010, the Indian generic drug maker said, citing IMS Health sales data.

Copyright © 2011 Dow Jones Newswires